EGFR and non-small cell lung carcinoma: This was achieved by testing the response of tumor cells, which were isolated from an MPE sample of a treatment‐naïve EGFR‐driven NSCLC patient, to targeted treatments and followed by correlation with genetic alterations and clinical outcomes.